The field of emerging MRI contrast agents (CA) is motivated by interest in more efficient CA that could be injected in lower quantities but still provide high-resolution 3D scans. The most effective CA must have sufficient kinetic stability, high relaxivity, high solubility, and must remain nontoxic during excretion. The Raymond group ligands are unique in that they use oxygen donor atoms to chelate Gd(III) or other lanthandes. The oxophilicity of Ln(III) allows for fewer ligand coordination sites while maintaining thermodynamic stability and therefore more sites for inner sphere water molecules (q). Relaxivity is directly proportional to q value; therefore, it is one of the most impactful parameters to improve. New capping moieties for HOPO chelators have been designed, synthesized, and evaluated for higher q values, higher solubility, and increased bioavailability.

Synthesis of novel capping moieties for increased q value in Gd-hydroxypyridinone (HOPO) chelators

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.